Protalix BioTherapeutics Inc’s filing revealed that its Director Schwartz Aharon acquired Company’s shares for reported $0.21 million on Jun 10 ’25. In the deal valued at $1.60 per share,129,000 shares were bought. As a result of this transaction, Schwartz Aharon now holds 303,000 shares worth roughly $0.5 million.
H.C. Wainwright reiterated its Protalix BioTherapeutics Inc [PLX] rating to a Buy in a research note published on June 08, 2020; the price target was $11. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who remained covering the stock and in mid April has reiterated a ‘”a Buy”‘ rating for it. Rodman & Renshaw began covering PLX with “Buy” recommendation on April 04, 2016. Jefferies revised its rating on April 23, 2015. It rated PLX as “a Buy” which previously was an “a Hold”.
Price Performance Review of PLX
On Tuesday, Protalix BioTherapeutics Inc [AMEX:PLX] saw its stock jump 1.86% to $1.64. Over the last five days, the stock has gained 15.49%. Protalix BioTherapeutics Inc shares have risen nearly 57.69% since the year began. Nevertheless, the stocks have fallen -12.77% over the past one year. While a 52-week high of $3.10 was reached on 05/01/25, a 52-week low of $0.82 was recorded on 06/23/25.
Levels Of Support And Resistance For PLX Stock
The 24-hour chart illustrates a support level at 1.6083, which if violated will result in even more drops to 1.5767. On the upside, there is a resistance level at 1.6633. A further resistance level may holdings at 1.6867.
How much short interest is there in Protalix BioTherapeutics Inc?
A steep rise in short interest was recorded in Protalix BioTherapeutics Inc stocks on 2025-07-31, growing by 0.36 million shares to a total of 3.63 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 3.27 million shares. There was a rise of 9.93%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 12, 2014 when R. F. Lafferty resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $5.
